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A 21-year-old woman with cystic fibrosis (CF) with recurrent
admissions for CF exacerbations, diabetes mellitus, and
allergic bronchopulmonary aspergillosis was hospitalized
with shortness of breath and hemoptysis. During her
course, she required intubation and was treated with several
antibiotics including polymyxin and inhaled tobramycin on
admission, then rifampin and intravenous (IV) tobramycin
(dose of 7mg/kg daily) beginning on hospital day 3. The
tobramycin troughs ranged between o0.2 and 0.4.
Initially, she had a chronic respiratory acidosis with
normal serum electrolytes and creatinine. On day 7, she
developed profound hypokalemia, hypomagnesemia, hypo-
calcemia, and metabolic alkalosis (Table 1), which persisted
for 2 weeks despite aggressive electrolyte repletion with
oral and IV potassium chloride, IV magnesium sulfate
(640mg/h), and IV calcium gluconate (400mg/h).
During the intensive care unit stay, the patient did not
receive any loop diuretics and her serum creatinine was stable.
The patient serum glucose levels were initially intermittently
high but the electrolytes disturbances persisted even after her
hyperglycemia was controlled on an IV insulin (mostly below
250mg/dl).
Additional evaluation showed serum parathyroid concen-
tration of 17pg/ml (10–65pg/ml), inappropriately low for the
level of hypocalcemia. The 24-h urine calcium was 440mg/24h.
The urinalysis was negative for glucosuria and proteinuria.
The fractional excretion of urate was 7.8% (normal: 6–20%); the
fractional excretion of phosphorus was 10.25% (normal: 5–20%).
What is your diagnosis?
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Table 1 | Blood and urinary blood tests
Blood tests Arterial blood tests Urine
Na
(mmol/l)
K
(mmol/l)
Cl
(mmol/l)
Bicarbonate
(mmol/l)
BUN
(mg/dl)
Crea
(mg/dl)
Corrected
calcium
(mg/dl)
Magnesium
(mg/dl)
Phosphate
(mg/dl) pH
pCO2
(mmHg)
pO2
(mmHg)
Bicarbonate
(mmol/l) pH
Na
(mmol/l)
K
(mmol/l)
Cl
(mmol/l)
FeMg
(%) TTKG
Normal
range
136–146 3.5–5.5 97–105 23–30 7–20 0.5–0.9 8.7–10.2 1.5–2.3 2.5–4.3 7.35–7.45 32–45 72–104 21–28
Day 0 137 3.6 97 35 13 0.6 9 2.4 3.2 7.35 70 134 38
Day 7 136 2.7 83 43 4 0.4 8.4 1.1 1.1 7.57 59 111 54.2 7 157 17 174 4.33
Day 10 129 2.5 73 39 6 0.4 6.5 0.5 1.6 7.58 51 73 47.7 7.5 119 75 191 57 17.2
Day 14 136 2.9 79 45 3 0.4 7.6 1.6 2.7 7.55 61 47 53.8 7 121 30 150 68 10.3
Abbreviations: BUN, blood urea nitrogen; Crea, creatinine; TTKG, transtubular potassium gradient.
Day 7: Onset of the metabolic alkalosis and other electrolytes disturbances.
Day 10: 3 days after intravenous repletion of potassium, calcium, magnesium, and phosphorus.
Day 14: Patient was on spironolactone for 2 days.
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The Diagnosis | Bartter-like syndrome
Serum and urinary electrolytes showed a metabolic alkalosis
with hypocalcemia, hypokalemia, and hypomagnesemia
associated with hyperchloruria, hypercalciuria, high trans-
tubular potassium gradient, and hypermagnesuria. The
presentation is consistent with a diagnosis of Bartter-like
syndrome secondary to aminoglycosides. The patient had no
evidence of proximal tubulopathy (no glucosuria, normal
fractional excretion of urate, and phosphate).
Aminoglycosides have excellent renal parenchymal pene-
tration and can induce nephrotoxicity through two differents
mechanisms: (1) megalin-induced endocytosis of the drugs
leading to lysosomal rupture and proximal tubular cellular
necrosis or (2) activation of the calcium-sensing receptors
(CaSR) mostly following chronic therapy with low concen-
trations. The CaSR is localized in different parts of the
nephron including the cortical thick ascending limb. The
CaSR seems to be stimulated by aminoglycoside anti-
biotics (neomycin, gentamicin, and tobramycin) through
a phosphatidylinositol 4,5 bisphosphate phospholipase C
(PIP2-PLC)–dependent pathway, leading to an increase in the
intracellular calcium, and inturn to a Bartter-like tubulo-
pathy.1 Other tubular dysfunctions described with amino-
glycoside include Fanconi-like syndrome and distal renal
tubular acidosis. Aminoglycoside antibiotics, which are
polyvalent cationic molecules, stimulate the CaSR, leading
to a decrease in NKCC2 luminal expression, which reduces
the luminal positive driving force resulting in calciuria and
magnesiuria.
Gentamicin infusion induces an increase in urinary
excretion of magnesium and calcium in both neonates and
healthy adults; these effects are transient.2 In a rat model,
gentamicin-induced urinary excretion of sodium, potassium,
calcium, and magnesium was accompanied by upregulation
of the CaSR and decrease in expression of Naþ -Kþ -2Cl
cotransporter. The clinical picture is compatible with type 5
Bartter-like syndrome.3
Several case reports of aminoglycoside-induced Bartter-
like syndrome were previously reported. The cumulative
aminoglycoside dosage was variable between these patients
(total gentamicin dose ranging between 0.04 g and 20 g).
The recovery period ranged from 7 to 210 days.3
In this case, IV tobramycin was discontinued on day 12.
The requirements for electrolytes repletion persisted even
after the patient was started on spironolactone 200mg twice
daily and amiloride 10mg daily. By day 25, the patient no
longer required continuous IV electrolyte repletion and was
able to maintain normal serum electrolyte levels, with the
exception of magnesium (Table 2). She was discharged with
normal serum electrolytes on magnesium oxide 1200mg
every 6 h, and amiloride 10mg once daily.
The literature to date has reported associations between
gentamicin/amikacin and Bartter-like syndrome. To our
knowledge, this is the first reported association with
tobramycin. We believe that exposure to such high doses of
tobramycin occurred given the high metabolism of amino-
glycosides in this cystic fibrosis patient.
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Table 2 | Blood and urinary blood tests (IV tobramycin started on day 3 and stopped on day 12, and inhaled tobramycin
stopped on day 19)
Blood tests Arterial blood tests Urine
Na
(mmol/l)
K
(mmol/l)
Cl
(mmol/l)
Bicarbonate
(mmol/l)
BUN
(mg/dl)
Crea
(mg/dl)
Corrected
calcium
(mg/dl)
Magnesium
(mg/dl)
Phosphate
(mg/dl) pH
pCO2
(mmHg)
pO2
(mmHg)
Bicarbonate
(mmol/l) pH
Na
(mmol/l)
K
(mmol/l)
Cl
(mmol/l)
FeMg
(%) TTKG
Normal
range
136–146 3.5–5.5 97–105 23–30 7–20 0.5–0.9 8.7–10.2 1.5–2.3 2.5–4.3 7.35–7.45 32–45 72–104 21–28
Day 14 136 2.9 79 45 3 0.4 7.6 1.6 2.7 7.55 61 47 53.8 7 121 30 150 68 10.3
Day 20 132 2.4 72 52 5 0.4 8.7 2.1 3.2 7.49 76 122 58 6.5 21 21 51 15 10.6
Day 25 135 4.9 83 40 8 0.5 9.6 1.1 5.1 7.45 63 80 44 8.5 10 44 57
Day 47 133 4.3 86 36 17 0.5 9.7 1.5 4.3
Abbreviations: BUN, blood urea nitrogen; Crea, creatinine; IV, intravenous; TTKG, transtubular potassium gradient.
Day 14: Patient was on spironolactone for 2 days.
Day 20: Amiloride 10mg daily added to spironolactone 100mg twice daily.
Day 25: Patient did not require electrolyte repletion except for per os magnesium.
Day 47: Discharged from the hospital.
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